A trial fibrillation (AF) is the most common sustained arrhythmia, affecting more than two million Americans. The prevalence of obstructive sleep apnea (OSA) in patients with atrial fibrillation is 32% to 49%. AF prevalence is directly correlated with the severity of obstructive sleep apnea (OSA). 1, 2 Mechanisms thought to be at least partly responsible for the interaction of AF and OSA include elevated intrathoracic pressure, increased autonomic nervous system activity, and inflammation. 3 A trend towards increased AF recurrence has been described in patients with untreated OSA after treatment for AF. 4 The risk of AF recurrence is related to the duration of oxygen saturation < 90% and the magnitude of the desaturation. 3 Patients have shown significant improvement both pre and post-ablation with the usage of both medication and CPAP. 1 The most important benefit of CPAP may be the reduction in the frequency of the large negative swings in intra thoracic pressure.
Support for the use of oral appliance therapy in OSA has risen with the recent publication research confirming the positive effect of oral appliance therapy on blood pressure and cardiovascular mortality. 5, 6 Non-compliant or non-tolerant CPAP patients may benefit from oral appliance therapy.
As a dentist when assessing the position of the mandible during the titration, one of our tools is pulse oximetry. What information can be gained by frequent use of pulse oximetry?
What is most significant when assessing the pulse oximetry? Does the oxygen nadir, the oxygen desaturation index, or the duration of time spent below 90% saturation contribute to the atrial fibrillation? What is the best way to manage these patients?
A 66-year-old, overweight (BMI 36.1) male presented with moderate OSA (AHI 17). His medical history included insulin dependent diabetes, hypertension, hypercholesterolemia, and atrial fibrillation. He had cardiac ablation in December 2012. He reported no occurrences of flutter and that he "feels better" since the ablation. He was not able to tolerate CPAP. He was fitted with an oral appliance in April 2013 at an initial advancement of 6 mm of a total protrusive range of 10 mm. Oximetry at the initial setting indicated suboptimal results, and the appliance was advanced to 8 mm and oximetry repeated. Pre-and post-treatment outcomes are shown in Table 1 . A second posttreatment oximetry was done 7 months later with no further advancement.
The patient's cardiologist reviewed the pulse oximetry results, concluding that the reduction in the total number of desaturations was helpful and the hypoventilation related to the obesity was not significant enough to use nocturnal oxygen at this time. As of September 2014, no recurrences of AF have been reported. A follow-up PSG with the appliance in place has been ordered.
Management of these patients might include a log of the time and circumstances of arrhythmic episodes. Aggressive advancement of the mandible to 60% to 70% of protrusion, and close communication with the patient at biweekly intervals may allow for more rapid reduction in symptoms. Regular nocturnal monitoring with pulse oximetry at different points of titration, and frequent communication with the cardiologist helps to improve outcomes. Patients are very grateful when they can finally sleep without the disruption of the atrial fibrillation episode.
Follow-up overnight PSG with the appliance in place after the airway is maximized is critical to determine the effectiveness. 
